Home  /  Resource Library  /  Ibrutinib Induces Durable Remissions in Treatment-Naive CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Ibrutinib Induces Durable Remissions in Treatment-Naive CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

ASH 2020: Phase II study examined the effectiveness of ibrutinib for first line treatment of chronic lymphocytic leukemia in patients with 17p deletion.